Pfizer Inc. (NYSE: PFE) announced today the completion of a global, ex-China, licensing agreement with 3SBio, Inc. (01530.HK) ...

Pfizer Inc. (NYSE:PFE) is among the 12 Best Ethical Companies to Invest in 2025. On July 24, 2025, Pfizer Inc. (NYSE:PFE) ...

As part of the agreement, which was signed in May 2025, 3SBio will receive $1.25bn, along with a $100m equity investment from ...

Pfizer agreed to an upfront payment of US$1.25 billion, US$150 million for mainland rights and a US$100 million equity ...

Moderna has scrapped plans to build an mRNA plant in Japan. Otsuka and Lundbeck's proposal for Rexulti as part of a PTSD ...

Pfizer inks $1.25 billion deal with 3SBio for cancer drug ...

Pfizer also has an option to obtain commercialization rights in China. Separately, Pfizer said it plans to invest $100 million in 3SBio equity after the licensing deal closes, which is expected in the ...

Northeastern Chinese company 3SBio to receive $1.25B, in addition to $100M equity investment, $150M for exclusive rights in ...

New capital, maturing pipelines, and a more global R&D mindset are pushing valuations higher, even as competition tightens.

Pfizer is on the brink of a major rebound, transitioning focus to oncology and potential blockbuster drugs after a sharp drop in COVID-related revenues. Pfizer’s stock has plummeted over 50% in the ...